Project: Development of a cost-effective vaccine against cervical cancer - a prophylactic approach

CERVI PRO aims to develop a cost-effective plastid-based prophylactic vaccine against cervical for high disease burdened developing countries such as Pakistan, from the start point of an existing prototype in tobacco. These vaccinea will be expressed in the form of L1 capsomeres directly coupled with Escherichia coli heat-labile enterotoxin subunit B (LTB) as adjuvant. This strategy makes simple and price reduced oral immunization possible delivered by a vaccine with enhanced immunogenicity.

Acronym CERVI PRO (Reference Number: 9817)
Duration 01/08/2015 - 01/08/2018
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 3

Project partner

Number Name Role Country
21911 BioEnergy GmbH & Consultant Coordinator Germany
21912 Geman Cancer Research Center Partner Germany
21913 Bionaturis Group Partner Spain